melphalan / Generic mfg. - LARVOL DELTA

Phase 1-2 Study of Total Bone Marrow Irradiation With Helicoidal Tomotherapy in 1st Myeloma Relapse (clinicaltrials.gov) - P=N/A | N=13 | Terminated | Sponsor: Institut Cancerologie de l'Ouest | Phase classification: P1/2 ➔ P=N/A

Phase classification • Hematological Malignancies • Multiple Myeloma • Oncology • CD34

Temporal trends in treatment patterns and overall survival for multiple myeloma management in Taiwan using the national health insurance claims database (ASH 2025) - "Since then, treatment for MM has continued to evolve, most notably with availability of anti-CD38 monoclonal antibodies such as daratumumab (D). We investigated temporal trends in MM treatment patterns and clinical outcomes from 2013 to 2022, a period encompassing onset of reimbursement for lenalidomide (R) in first line (1L) in patients with transplant-ineligible (TI) MM from February 2020, and D for second line (2L) and beyond from April 2020...Between study periods, VTd use in 1L (approximately 50% of patients) was unchanged, use of V(bortezomib)R-dexamethasone(d) increased from 0-17.59%, and use of regimens containing melphalan and alkylators decreased... The NHIRD provides health insurance for the whole population of Taiwan, allowing complete and longitudinal data collection across all treatment settings. We observed increased uptake of novel agents after their reimbursement under the National Health Insurance that coincided with a decrease in attrition rates and an..."

Claims database • Clinical • Reimbursement • US reimbursement • Hematological Malignancies • Multiple Myeloma

Outcomes of allogeneic hematopoietic stem cell transplantations (HSCT) for treatment of secondary primary malignancies arising post-autologous HSCT for multiple myeloma (ASH 2025) - "As conditioning regimens, 12 patients received Fludarabine/Busulfan, and 5 patients received Fludarabine/Melphalan...For GVHD prophylaxis, 6 patients received Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil (MMF); 9 patients received Thymoglobulin, Tacrolimus, and MMF; 1 patient received Thymoglobulin, Sirolimus, and MMF; 1 patient received Tacrolimus, Methotrexate, and Abatacept...Limitations of the outcome data include a relatively small population that underwent Allo-HCST, likely lower than the true number of patients with SPM following Auto-HSCT due to them either not returning to the center or opting against Allo-HSCT for treatment. This data adds to the collective understanding of the associated risks and benefits of Allo-HSCT for treatment of hematological SPM following Auto-HSCT for MM."

Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Multiple Myeloma • Myelodysplastic Syndrome • Oncology • Transplantation • TP53

Long-term HIV remission of a perinatally infected individual, following a hematopoietic cell transplantation from a CCR5Δ32 homozygous donor for multiple myeloma: The kyiv patient (ASH 2025) - "Complete remission (CR) was achieved after one cycle of melphalan/prednisone and local radiotherapy, but an abdominal relapse occurred six months later. Despite subsequent lines of therapy (bortezomib(bort)/lenalidomide(lena)/dexamethasone(dexa) and bendamustine/bort/dexa), the extramedullary multiple myeloma (MM) progressed. Remission was achieved after dexa/thalidomide/cisplatin/doxorubicin/cyclophosphamide/etoposide (DT-PACE) and an autologous HCT performed on 1/2021...Allogeneic HCT was performed in 8/2022 after fludarabine/melphalan conditioning and anti-thymocyte globulin from a CCR5-Δ32homozygous, unrelated HLA-matched donor; cyclosporine/methotrexate was utilized as graft-versus-host diseas e (GVHD) prophylaxis... To our knowledge, this represents the first report of ART-free HIV RNA suppression following allogeneic HCT with a CCR5Δ32homozygous donor in an individual perinatally infected with HIV. Despite the differences in the latent reservoir and the mechanism..."

Clinical • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Human Immunodeficiency Virus • Immunology • Infectious Disease • Multiple Myeloma • Plasmacytoma • Transplantation • CCR5 • CD4 • CD8

Results of abatacept addition to post transplant cyclophosphamide-based GVHD prophylaxys in allogeneic hematopoyetic stem cell transplantation (ASH 2025) - "All patients received peripheral blood as graft source and all patients received GVHD prophylaxis with ABA in combination with PTCY, tacrolimus, and mycophenolate mofetil...Reduced-intensity conditioning regimens were used in the majority of patients in both cohorts (88.2% vs 93.4%, p=0.5), most commonly conditioning included busulfan-fludarabine or busulfan-cyclophosphamide-fludarabine. In the +56 cohort, 2 patients received clofarabine-melphalan, according to internal protocol, due to disease persistence prior to transplant.With a median follow-up of 15.7 months (range 7.4–31.1), estimated 1-year PFS and OS were 66% (IC95%= 0.5-0.7) and 72% (IC95%= 0.5-0.8)... Our experience suggests, compared with previous analysis ( P Fernandez-Caldas. EBMT 2024 ), that addition of ABA to PTCY-based prophylaxis, in peripheral blood stem cell setting, may reduce GVHD and allow early immunosuppression withdrawal without increasing GVHD rates, though sample size is limited."

Post-transplantation • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome • Transplantation • CTLA4

Clinical efficacy and safety for pediatric patients with severe combined immunodeficiency disease treated with modified allo-haploidentical stem cell transplantation (ASH 2025) - "A modified transplant protocol with PTCy (25-35 mg/kg/day on days +3 and +4) was performed, including fludarabine 160 mg/m2 divided into 4 days on day -8 to -5, Melphalan 100 mg/m 2 divided into two days on day -3, -2, Cyclophosphamide 20mg/kg/day on day -5, -4 and porcrine anti-human lymphocyte immunoglobulin 25mg/kg/d on day -8 to -6. Our modified protocol provides a new treatment method for SCID patients without suitable donor, expanded donor pool. Using the reduced intensity conditioning regimen, reduced toxicity and heavy economic burden, lower rate of GVHD increased high quality of life. Due to the small sample size, further confirmation is needed with a larger number of cases."

Clinical • Bone Marrow Transplantation • Genetic Disorders • Graft versus Host Disease • Immunology • Infectious Disease • Novel Coronavirus Disease • Pediatrics • Primary Immunodeficiency • Pulmonary Disease • Respiratory Diseases • Transplantation

FluMel100 with post-transplant cyclophosphamide: A safe and effective regimen for patients aged ≥75 years with MDS and AML (ASH 2025) - "Many published studies in older adults have often utilized non-myeloablative and reduced intensity conditioning regimens, including fludarabine/total body irradiation, fludarabine/melphalan (FluMel) and fludarabine/busulfan combined with varied graft versus host disease (GVHD) prophylaxis approaches...They underwent re-induction therapy with cladribine, low dose cytarabine and venetoclax, achieving a complete remission, followed by donor leukocyte infusion (DLI)... Eight patients were included: seven with AML (n=7) and one had MDS (n=1), Kanofsky Performance Status range 80-90%, HCT-CI (Comorbidity Index) range 0-7. All patients received peripheral blood stem cell (PBSC) grafts from human leukocyte antigen (HLA) matched unrelated donors (MUD). PT-Cy dose was 80 mg/kg (n= 7) and 50mg/kg (n= 1)."

Clinical • Post-transplantation • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Geriatric Disorders • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome • Transplantation • CD33 • HLA-DPB1

Total marrow irradiation-based, intensified reduced-intensity conditioning regimen for haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide: A prospective study (ASH 2025) - P1 | "Patients received Haplo-HCT with a conditioning regimen consisting of intravenous busulfan (total area under the curve, AUC, of 9,600 µM*min), fludarabine (total dose of 150 mg/m²), and total marrow irradiation (6 Gy, administered in two days with two daily doses of 1.5 Gy). In one patient, melphalan 50 mg/m2 was substituted for busulfan...These results show a good balance between the effectiveness of the conditioning regimen and toxicity. Future studies should confirm these promising results in haplo-HCT with TMI-based RIC conditioning using a larger patient cohort.Acknowledgements The authors declare no conflict of interest."

Clinical • Post-transplantation • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Chronic Myelomonocytic Leukemia • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Lymphoma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • Transplantation

Paroxysmal nocturnal hemoglobinuria: Transplant experience using post-transplant cyclophosphamide in a resource-limited setting (ASH 2025) - "On the other hand, complement inhibitors (eculizumab, ravulizumab) have emerged as effective treatments with lower toxicity, though they are not curative...MRD transplant patients received Fludarabine/Melphalan (Flu/Mel) and haploidentical transplant received standard Baltimore protocol...Among them, two patients developed CMV reactivation, which was well controlled with valganciclovir... Allogeneic HSCT remains a potentially curative but high risk option for PNH patients, particularly in resource limited settings. Our experience highlights the significant transplant related morbidity and mortality, even with modern GVHD prophylaxis such as PTCy.Given the availability of safer, though non-curative, therapeutic alternatives like complement inhibitors, urgent advocacy is needed. Patient groups, healthcare providers, policy-makers, and international aid organizations must collaborate to improve access to life-saving treatments in low-income countries."

Post-transplantation • Aplastic Anemia • Bone Marrow Transplantation • Cardiovascular • Chronic Graft versus Host Disease • Complement-mediated Rare Disorders • Febrile Neutropenia • Gastroenterology • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Inflammation • Mucositis • Myelodysplastic Syndrome • Paroxysmal Nocturnal Hemoglobinuria • Pneumonia • Rare Diseases • Respiratory Diseases • Thrombosis • Transplantation

Outcomes of myeloablative vs reduced and non-myeloablative conditioning in MRD-negative AML and ALL with ptcy-based GVHD prophylaxis (ASH 2025) - "In the current post-transplant cyclophosphamide (PTCY) era, outcomes may differ given the widespread use of PTCY-based graft-versus-host disease (GVHD) prophylaxis...Reduced intensity conditioning included fludarabine 30mg/m 2 for 4 consecutive days plus 8 Gy TBI, or fludarabine plus either melphalan or busulfan, with 2 Gy TBI...All patients received PTCY in combination with a calcineurin inhibitor and mycophenolate mofetil as GVHD prophylaxis... In MRD-negative AML and ALL patients undergoing allo-HSCT with PTCY-based GVHD prophylaxis, NMA regimens appear to offer comparable survival and GVHD outcomes to MAC, with potentially lower toxicity. These findings suggest NMA conditioning may be a viable and safer alternative to MAC in select MRD-negative patients in the PTCY era."

Minimal residual disease • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia

An evolving landscape – how changing conditioning regimes can improve myelofibrosis transplant outcomes. (ASH 2025) - "Of the 16 cases, seven received Fludarabine/Busulphan/Antithymocyte globulin (Flu/Bu/ATG) conditioning (Fludarabine 30mg/m 2 day -9 to day -5, Busulphan 3.2mg/kg on day -4 and day -3 and rabbit ATG 2.5mg/kg on day -2 and day -1), seven underwent Fludarabine/Cyclophosphamide (Flu/Cy) conditioning (Fludarabine 25mg/m 2 day -6 to day -2 and Cyclophosphamide 1g/m 2 on day -3 and day -2), and two received Fludarabine/Melphalan (Flu/Mel) (Fludarabine 25mg/m 2 day -6 to day -2 and Melphalan 100mg/m 2 on day -2)...Therapies included Ruxolitnib, Momelotinib, splenic irradiation, Hydroxycarbamide, Danazol, Interferon, Cyclophosphamide, Anagrelide, Thalidomide, Panobinostat and Navitoclax...Although limited by a small sample size, these findings indicate that the Flu/Bu/ATG conditioning regimen may be associated with improved outcomes, thereby supporting its adoption as the preferred approach for patients undergoing allogeneic stem cell transplantation for myelofibrosis as per BSH..."

Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Infectious Disease • Myelofibrosis • Pneumonia • Respiratory Diseases • Transplantation • ASXL1 • CALR • JAK2 • SF3B1 • U2AF1

Diluting high yield hematopoietic stem cell apheresis for autologous transplantation results in high viability of fresh grafts beyond 72h (ASH 2025) - "At the Instituto de Prevision Social all lymphoma patients are transplanted with fresh grafts using a shortened BEAM protocol with time to collect to infusion of 96 hours (BCNU d-4; Ara-C d-4, d-3, d-2; Etoposide d-4, d-3, d-2; Melphalan d-2) and minimum CD34+ cells of 2,5 x 10*6...All patients were mobilized with GCSF +/- Plerixafor... While this is a very limited study due to number of participants, its retrospective nature and single center experience the data suggests diluting high yield apheresis products result in high viability of HPSC beyond 72 hours. Any HCT Program should aim to have cryopreservation facilities available as there are some patients that cannot be transplanted safely without said capacities. However, this may not be the case for Lymphoma patients."

Hematological Malignancies • Immunology • Lymphoma • Multiple Myeloma • Solid Tumor • Transplantation • CD34

Budesonide for melphalan-induced intestinal mucositis in autologous hematopoietic stem cell transplant: Rapid resolution with short-course therapy (ASH 2025) - "Short-course oral budesonide appears to be a safe and effective strategy for the rapid resolution of persistent post-engraftment diarrhea due to melphalan-induced intestinal mucositis. Initiation of BUD facilitated early discharge and reduced morbidity without observable adverse effects. Larger prospective studies are warranted to validate these findings."

Acute Lymphocytic Leukemia • B Cell Lymphoma • Bone Marrow Transplantation • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Leukemia • Lymphoma • Mucositis • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Rotavirus Infections • Transplantation

Anti-CD38-based quadruplet versus triplet induction regimens in transplant-ineligible newly diagnosed multiple myeloma: A systematic review and meta-analysis (ASH 2025) - "Introduction Triplet induction therapy with either daratumumab, lenalidomide, and dexamethasone (D-Rd) or bortezomib, lenalidomide, and dexamethasone (VRd) has long been the standard of care for transplant-ineligible patients with newly diagnosed multiple myeloma (TIE-NDMM)...The quadruplet regimens comprised an anti-CD38 monoclonal antibody (daratumumab or isatuximab), a proteasome inhibitor (bortezomib or carfilzomib), an immunomodulatory drug (lenalidomide) or alkylator (melphalan or cyclophosphamide), and a corticosteroid...While quadruplet regimens were associated with higher rates of SAEs and grade 3-4 infections, no significant differences were observed in the rates of grade 3-4 neutropenia or thrombocytopenia. Careful patient selection is essential to optimize outcomes and mitigate treatment-related toxicity."

Retrospective data • Review • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Thrombocytopenia • Transplantation

Outcomes of patients with light-chain amyloidosis after heart transplantation: A single center cohort. (ASH 2025) - "One patient underwent an upfront autologous stem cell transplant (ASCT), five patients (55.5%) received VCD (bortezomib, cyclophosphamide and dexamethasone), one bortezomib plus dexamethasone, one daratumumab alone and one combined with VCD...Four patients received high-dose melphalan as consolidation between 6 and 16 months after HT...Early anti-plasma cell therapy and supportive care are crucial, as well as consolidation with ASCT after heart transplantation in order to obtain high-quality hematologic responses and better outcomes. Future multicentre studies with larger cohorts are warranted to further support these results."

Clinical • Amyloidosis • Cardiovascular • Congestive Heart Failure • Cytomegalovirus Infection • Heart Failure • Hematological Malignancies • Infectious Disease • Renal Disease • Respiratory Diseases • Transplantation

Talquetamab induces deep responses in heavily pre-treated patients with systemic light-chain amyloidosis (ASH 2025) - "All were refractory to daratumumab, bortezomib, cyclophosphamide, and pomalidomide; four were refractory to lenalidomide and belantamab mafodotin; one patient with t(11; 14) was refractory to venetoclax. Three relapsed after anti-BCMA academic CAR-T (HBI0101). Additional therapies included ixazomib (2), carfilzomib (1), elotuzumab (1), and melphalan (1)... Talquetamab produced deep and durable hematologic responses in heavily pretreated patients with R/R AL amyloidosis. Assessment of organ response potential was limited by irreversible organ dysfunction at baseline and short follow-up. Treatment was feasible, including in end-stage renal disease, and the safety profile was manageable without unexpected toxicities."

Clinical • Amyloidosis • Cardiovascular • Congestive Heart Failure • Dental Disorders • Heart Failure • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Nephrology • Renal Disease • Septic Shock • Thrombocytopenia • Xerostomia

Bone marrow adipose tissue is enriched in multiple myeloma cells (ASH 2025) - "In vitro , a 4-hour treatment of isolated fat-associated and aspirate-associated cells with bortezomib, melphalan, dexamethasone, or thalidomide revealed a high inter-patient heterogeneity, as in a subset of patients adipose-associated MM cells reacted less to treatment compared to MM cells from the aspirate (measured as percentage of viable MM cells after treatment). The specific molecular interactions between adipocytes, MM cells, and immune cells remain to be identified. Furthermore, as the amount (and presence) of BMAT is highly heterogenous per patient, the exact significance of fat-associated MM cells and their contribution to disease burden has to be assessed."

Hematological Malignancies • Monoclonal Gammopathy • Multiple Myeloma • FABP5 • IRF4 • NCAM1

Consolidation of dual MAPK inhibitor therapy by allograft in histiocytic sarcoma: A report of two cases (ASH 2025) - "Transplant proceeded using fludarabine 150mg/m 2 and melphalan 140mg/m 2 with post-grafting cyclophosphamide, mycophenolate mofetil and tacrolimus for graft-versus-host disease (GvHD) prophylaxis...He remains well on dabrafenib and trametinib in CMR at 16-months post-transplant...To consolidate this response, allograft from a haploidentical donor was performed using fludarabine 150mg/m 2 and melphalan 140mg/m 2 with post-grafting cyclophosphamide and ciclosporin for GvHD prophylaxis... These 2 cases suggest that allograft is feasible on dual MAPK inhibitor therapy and may have potential efficacy as consolidation for high-risk visceral HS. Withdrawal of inhibitors and longer follow up are required to determine the durability of remission with this approach."

Clinical • Cough • Gastroenterology • Gastrointestinal Disorder • Graft versus Host Disease • Immunology • Infectious Disease • Respiratory Diseases • Sarcoma • Solid Tumor • Tuberculosis • BCL6 • CCND1 • CD14 • CD163 • CD1a • KRAS • MAP2K1

Checkpoint inhibitors improve progression free survival after autologous transplant despite poorer pre-transplant response (ASH 2025) - "Introduction The checkpoint inhibitors (CI) nivolumab and pembrolizumab which target PD1 are established treatments for relapsed/refractory classic Hodgkin Lymphoma (cHL)...44 received brentuximab vedotin (BV)...All patients were conditioned with LEAM (lomustine, etoposide, cytarabine, melphalan)...CI treatment prior to ASCT may alter cHL disease biology leading to increased sensitization to subsequent high dose cytotoxic chemotherapy although more exploratory data assessing the mechanism is needed. We are planning a multi-centre analysis to investigate further."

Checkpoint inhibition • Pre-transplantation • Cardiovascular • Classical Hodgkin Lymphoma • Diabetes • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Lymphoma • Metabolic Disorders • Oncology • Pneumonia • Transplantation

Allogeneic hematopoietic stem cell transplantation in treatment of Shwachman- diamond syndrome: A Report of 25 Pediatric cases from a Single center (ASH 2025) - "All patients used myeloablating conditioning.The regimen of the case with AML consisted of busulfan, fludarabine, cytarabine, cyclophosphamide and anti-thymocyte globulin(ATG)...All were given cyclosporine and mycophenolate mofetil to prevent graft-versus- host disease(GVHD). Balliximab was given at +1 day to the patients whose donor was MMRD and methotrexate was given at +1,+4,+7,+11 days to the patients whose donor was MMUD or UCB...Melphalan was administered before donor peripheral blood stem cell infusion, resulting in negative MRD... Allo-HSCT is an effective treatment for SDS complicated with severe hematological abnormalities.Compared with MMRD and MMUD HSCT, the incidence of GVHD in CBT is lower. MDS complicated with both complex karyotype and Tp53 mutation was associated with an extremely poor prognosis."

Clinical • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome • Neutropenia • Palliative care • Pediatrics • Thrombocytopenia • Transplantation • TP53

Transplant outcomes of b acute lymphoblastic leukemia treated with inotuzumab ozogamicin with mini–Hyper-CVD based chemo-immunotherapy (ASH 2025) - "The chemotherapy protocol consisted of mini-CVD part A(cyclophosphamide at 150mg/m2 x 4 doses, dexamethasone 20mg x 4 days, vincristine 1.5mg on day 1and 8, but no anthracycline) or part B (methotrexate 250mg/m2 and cytarabine 0.5gm/m2 x 4 doses)...CD22 expression was positive in 22patients (91.4%), Other therapies added to this regimen included tyrosine kinase inhibitors in 3 patients(12.5%), venetoclax in 13 patients (54%), and rituximab in 11 patients (45.3%).The overall response rate (ORR) was 95.8% (n = 23)...Conditioning regimens included Flu/TBI in 12 patients, Fludarabine(Flu)/Melphalan (Mel) in 2 patients, Flu/Mel/Total Body Irradiation (TBI) in 4 patients,Flu/Cyclophosphamide/TBI in 2 and Flu/Thiotepa/TBI in 1. Graft versus host disease prophylaxis varied,with post-transplant cyclophosphamide (PTCy) /Cyclosporine (CsA)/mycophenolate mofetil (MMF) used in15 patients, PTCy/CSA in 5, and CSA/methotrexate in 1...InO mini CVD is a feasible and effective salvage..."

IO biomarker • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Leukemia • Neutropenia • Septic Shock • Transplantation • CD20 • CD22 • CD34 • TP53

Safety of myeloablative total marrow and lymphoid irradiation versus chemotherapy-based conditioning in adults with high-risk acute lymphoblastic leukemia in a limited resources setting (ASH 2025) - "TMLI-based conditioning consisted ofcyclophosphamide (Cy) 350 mg/m2 and fludarabine (Flu) 25 mg/m2 (day -6 to day -4) followed by TMLItotal dose of 12 Gy from day -3 to day -1, delivered in 6 fractions of 2 Gy every 12 hours over threeconsecutive days, delivered using a tomotherapy system...As prophylaxis for graft-versus-host disease (GVHD), patients received post-transplantcyclophosphamide, tacrolimus and mycophenolate mofetil. Patients in the historical cohort receivedCyFlu plus melphalan 140 mg/m2 plus 2 Gy of TBI for haploidentical recipients...The median number of prior treatment lines was 2 (range 1–4) 50% were blinatumomab-exposed and n=2 had a history of prior HSCT...The 1-year OS inTMLI was 76.2% vs 93% in the control group (p=.15). RFS rates were 72% in TMLI vs 78.5% in controls (p =0.9); 1-year NRM was 4.5% in TMLI vs 9.5% in controls (p=0.7).ConclusionsMyeloablative doses of TMLI have a similar safety profile to reduced intensity..."

Clinical • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Febrile Neutropenia • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Mucositis • Neutropenia

Outcomes and associated factors after melphalan 140 mg/m² autologous hematopoietic cell transplantation for multiple myeloma in patients over 70 years of age (ASH 2025) - "Age alone did notpredict adverse outcomes. Higher HCT-CI, lower Karnofsky performance status, and ISS Stage III weresignificant determinants of worse outcomes, emphasizing the importance of comprehensive riskstratification beyond age in selecting older adults for auto-HCT."

Clinical • Hematological Malignancies • Multiple Myeloma • Transplantation

Optimizing patient selection to decrease non-relapse mortality with reduced intensity conditioning: A validation study using the CIBMTR dataset (ASH 2025) - "The analysis was further restricted to patients who received conventional GVHD prophylaxis with acalcineurin inhibitor plus either methotrexate or mycophenolate mofetil, and one of four commonly usedconditioning regimens: (1) total body irradiation plus cyclophosphamide (CyTBI); (2) busulfan pluscyclophosphamide (BuCy); (3) fludarabine plus busulfan (FluBu); or (4) fludarabine plus melphalan(FluMel). ConclusionThe RICE score successfully identified patients who benefit from lower NRM of RIC in the CIBMTR dataset,validating findings reported using a Japanese cohort. These results support the importance of the RICEscore in guiding personalized clinical decision-making of conditioning intensity."

Clinical • Graft versus Host Disease • Immunology

Romiplostim N01 enhances platelet engraftment in ASCT using non-cryopreserved pbscs for plasma cell neoplasms: A single-center phase II study in China (ASH 2025) - "Other baseline characteristics were also comparable, such as Durie-Salmon stage, R-ISS stage, HCT-CI scpre, disease response prior to HSCT, Plerixafor use, single dayapheresis and Melphalan dose.All patients achieved hematologic engraftment. At a median follow-up of 10.8 months, 2-year overall survival did not differsignificantly (85.7% ± 13.2% vs 84.4% ± 8.3%, P=0.717).In patients with plasma cell neoplasms undergoing ASCT with non-cryopreserved PBSCs, RomiplostimN01 significantly accelerated platelet engraftment and reduced hospitalization costs withoutcompromising safety. These findings support its use as an effective alternative to traditionalcryopreserved PBSCs with rhTPO support."

Clinical • P2 data • Amyloidosis • Bone Marrow Transplantation • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Mucositis • Multiple Myeloma • Neutropenia • Plasmacytoma